Matches in Nanopublications for { ?s ?p "[We now show that cancer cells that have acquired resistance to single-target EGFR inhibitors through upregulation of AXL or loss of E-cadherin remain sensitive to CUDC-101, which inhibits MET- and AXL-mediated signaling, restores E-cadherin expression, and reduces cell migration.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- NP258290.RA3ATWlDkVAIZIdqh4peBHsERcaBzWfZKSBX39OPBqaM8130_assertion description "[We now show that cancer cells that have acquired resistance to single-target EGFR inhibitors through upregulation of AXL or loss of E-cadherin remain sensitive to CUDC-101, which inhibits MET- and AXL-mediated signaling, restores E-cadherin expression, and reduces cell migration.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP258290.RA3ATWlDkVAIZIdqh4peBHsERcaBzWfZKSBX39OPBqaM8130_provenance.
- NP258189.RALeUpRe8IDR_tm-KB2kQeHquLKKAD1aQVzSuet5aW2SA130_assertion description "[We now show that cancer cells that have acquired resistance to single-target EGFR inhibitors through upregulation of AXL or loss of E-cadherin remain sensitive to CUDC-101, which inhibits MET- and AXL-mediated signaling, restores E-cadherin expression, and reduces cell migration.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP258189.RALeUpRe8IDR_tm-KB2kQeHquLKKAD1aQVzSuet5aW2SA130_provenance.